γ-Hydroxybutyric acid
| Clinical data | |
|---|---|
| Other names | |
| Addiction liability | High[3] |
| Routes of administration | By mouth, intravenous |
| Drug class | GABA analogue, GHB receptor agonists—GABA receptor agonist; Psycholeptic;
Depressant; Hypnotic Sedative |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 25% (oral) |
| Metabolism | 95–98%, mainly liver, also in blood and tissues[12] |
| Onset of action | Within 5–15 minutes[11] |
| Elimination half-life | 30–60 minutes |
| Excretion | 1–5%, kidney[12] |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.218.519 |
| Chemical and physical data | |
| Formula | C4H8O3 |
| Molar mass | 104.105 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
γ-Hydroxybutyric acid, also known as gamma-hydroxybutyric acid, GHB, or 4-hydroxybutanoic acid, is a naturally occurring neurotransmitter and a depressant drug. It is a precursor to GABA, glutamate, and glycine in certain brain areas. It acts on the GHB receptor and is a weak agonist at the GABAB receptor. GHB has been used in medicine as a general anesthetic and as treatment for cataplexy, narcolepsy, and alcoholism.[13][14] It is also used illicitly for performance enhancement, date rape, and recreation.[15]
It is commonly used in the form of a salt, such as sodium γ-hydroxybutyrate (NaGHB, sodium oxybate, or Xyrem) or potassium γ-hydroxybutyrate (KGHB, potassium oxybate). GHB is produced as a result of fermentation, and is found in small quantities in some beers and wines, beef, and small citrus fruits.[16]
Succinic semialdehyde dehydrogenase deficiency causes GHB to accumulate in the blood.
- ^ "Pingers, pingas, pingaz: how drug slang affects the way we use and understand drugs". The Conversation. 8 January 2020. Archived from the original on 15 January 2021. Retrieved 13 May 2023.
- ^ "GHB/GBL "G"". Archived from the original on 24 May 2024. Retrieved 24 May 2024.
- ^ Tay, E., Lo, W. K. W., & Murnion, B. (2022). Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse. Substance Abuse and Rehabilitation, 13, 13–23. doi:10.2147/SAR.S315720
- ^ "Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024". 30 May 2024.
- ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
- ^ Cite error: The named reference
Xyrem FDA labelwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Lumryz FDA labelwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Xywav FDA labelwas invoked but never defined (see the help page). - ^ "What is GHB?" (PDF). U.S. Drug Enforcement Administration. Archived (PDF) from the original on 17 October 2020. Retrieved 6 March 2022.
- ^ Cite error: The named reference
DEAwas invoked but never defined (see the help page). - ^ Riviello RJ (2010). Manual of forensic emergency medicine : a guide for clinicians. Sudbury, MA: Jones and Bartlett Publishers. p. 42. ISBN 978-0763744625.
- ^ a b Cite error: The named reference
autowas invoked but never defined (see the help page). - ^ "Sodium Oxybate: MedlinePlus Drug Information". Nlm.nih.gov. 28 July 2010. Archived from the original on 11 April 2010. Retrieved 1 August 2010.
- ^ Benzer TI, Cameron S (8 January 2007). VanDeVoort JT, Benitez JG (eds.). "Toxicity, Gamma-Hydroxybutyrate". eMedicine. Archived from the original on 28 November 2021. Retrieved 16 January 2007.
- ^ Cite error: The named reference
dea-daterapewas invoked but never defined (see the help page). - ^ Weil A, Winifred R (1993). "Depressants". From Chocolate to Morphine (2nd ed.). Boston/New York: Houghton Mifflin Company. p. 77. ISBN 978-0-395-66079-9.